论文部分内容阅读
本文报道四川省１００例复、难治肺结核菌阳病人的耐药情况。１００例复、难治肺结核菌阳病例总和耐药率为９８％。九种抗结核药物中临床常用（ＩＮＨ、ＳＭ、ＲＦＰ、ＥＭＢ）耐药率普遍偏高，尤以ＲＦＰ最高，达８４％。大多数复、难治肺结核菌阳病人，对新药奥复星、力克肺疾敏感，提示奥复星和力克肺疾可用于复、难治肺结核病人的联合用药。另外，还必须重新评价ＰＡＳ在复、难治病例化疗的地位。双耐及多耐中，耐三药以上者占８４％。常用四药中，耐ＨＲ者５４例，多重耐药率为５４％，如此高的耐药率，应引起足够的认识。
This article reports 100 cases of Sichuan Province, complex, refractory tuberculosis Yang disease resistance. 100 cases of complex, refractory pulmonary tuberculosis positive cases of total resistance rate of 98%. The common clinical resistance (INH, SM, RFP, EMB) in nine kinds of anti-TB drugs was generally high, especially in RFP, up to 84%. Most complex and refractory pulmonary tuberculosis positive patients, the new drug Austrian Fosun, Lectra lung disease sensitive, suggesting that Austria Fosun and Lectra pulmonary disease can be used for complex, refractory pulmonary tuberculosis patients combined. In addition, you must also re-evaluate the PAS complex, refractory cases of chemotherapy status. Double resistant and multi-resistant, resistant to more than three drugs accounted for 84%. Of the four commonly used drugs, 54 were resistant to HR and the multi-drug resistance rate was 54%. Such a high drug resistance rate should arouse sufficient knowledge.